Last reviewed · How we verify
Chiauranib
Chiauranib is a Small molecule drug developed by Chipscreen Biosciences, Ltd.. It is currently in Phase 3 development. Also known as: CS2164.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chiauranib |
|---|---|
| Also known as | CS2164 |
| Sponsor | Chipscreen Biosciences, Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PHASE3)
- Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) (PHASE2)
- A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (PHASE2)
- A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer (PHASE1, PHASE2)
- Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer (PHASE3)
- Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (PHASE3)
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chiauranib CI brief — competitive landscape report
- Chiauranib updates RSS · CI watch RSS
- Chipscreen Biosciences, Ltd. portfolio CI
Frequently asked questions about Chiauranib
What is Chiauranib?
Who makes Chiauranib?
Is Chiauranib also known as anything else?
What development phase is Chiauranib in?
Related
- Manufacturer: Chipscreen Biosciences, Ltd. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: CS2164
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing